Budesonide 9 mg Induction Therapy for Mild Ileocecal Crohn’s Disease

Treatment Duration

• In patients with mild‑to‑moderate ileocecal Crohn’s disease (CDAI < 300), a regimen of oral budesonide 9 mg once daily for exactly 8 weeks induces remission in roughly 51 % of patients, compared with 20 % on placebo, indicating the 8‑week course achieves the maximal remission benefit. 1
• Remission rates plateau after the 8‑week period, supporting this fixed duration as the optimal induction length. 1
• The median time to symptomatic remission is 3–4 weeks; therefore, clear clinical improvement should be observable by the fourth week of therapy. 2

Monitoring Response

• Symptomatic response should be assessed between weeks 4 and 8; if no improvement is seen by week 4, escalation to systemic corticosteroids or alternative therapies is recommended. 2
• Clinical benefit is expected to be evident within 1–2 months; persistent lack of response warrants therapeutic modification. 2

Tapering Schedule

• After achieving remission at week 8, budesonide should be tapered over 1–2 weeks rather than stopped abruptly to reduce the risk of symptom recurrence. 1
• The British Society of Gastroenterology specifically advises this 1–2‑week taper, reflecting budesonide’s lower systemic exposure compared with systemic steroids, which typically require a 6–8‑week taper. 1

Maintenance Recommendations

• Budesonide is not recommended for maintenance therapy beyond the initial 8‑week induction plus taper; prolonged use offers no additional benefit and increases the risk of adverse effects such as adrenal suppression and bone loss. [2][3]
• Patients who need ongoing treatment after taper should be transitioned to established maintenance agents (e.g., thiopurines, biologics, or small‑molecule therapies) rather than continuing budesonide. 3

Disease Severity Considerations

• Budesonide is effective only for disease confined to the ileum and/or ascending colon; it has not demonstrated benefit for distal colonic inflammation. [1][3]
• In severe Crohn’s disease (CDAI > 300), budesonide is inferior to systemic corticosteroids such as prednisolone and should not be used. 1

Budesonide Therapy for Crohn's Disease

Initial Dosing and Efficacy

• The European Crohn’s and Colitis Organisation recommends budesonide 9 mg once daily as the first-line dose for mild to moderate ileocecal Crohn's disease, with a treatment duration of 8 weeks to induce remission 4, 5
• Budesonide achieves remission rates of approximately 51% compared to 20% with placebo in patients with mild to moderate ileocecal Crohn's disease 4

Disease Severity and Location Considerations

• The American Gastroenterological Association suggests that budesonide is appropriate only for mild to moderate disease (CDAI <300), and in severe disease (CDAI >300), systemic corticosteroids should be used instead 4
• Budesonide is effective for ileocecal and proximal colonic disease but has no proven benefit for distal colonic inflammation 4, 6

Tapering Schedule

• The British Society of Gastroenterology recommends tapering budesonide over 1-2 weeks after achieving remission, rather than abruptly discontinuing 4, 7, 6

Monitoring Response and Maintenance Therapy

• The American College of Gastroenterology suggests evaluating for symptomatic response between 4-8 weeks to determine if therapy modification is needed 5, 7, 6
• The European Crohn’s and Colitis Organisation recommends against using budesonide for maintenance therapy in Crohn's disease, as it is ineffective for maintaining remission and prolonged use is associated with significant adverse effects 5, 7, 6, 8

Safety Considerations

• The National Institute for Health and Care Excellence notes that budesonide has significantly fewer glucocorticoid-related adverse effects compared to prednisolone due to its high first-pass hepatic metabolism and low systemic bioavailability 8
• The American College of Gastroenterology recommends monitoring for adrenal suppression with prolonged use and being aware of drug interactions with CYP3A4 inhibitors (ketoconazole, ritonavir) which can increase systemic exposure 8